In:
International Journal of Cancer, Wiley
Abstract:
Women treated for CIN2 /3 remain at increased risk of recurrent CIN and cervical cancer, and therefore posttreatment surveillance is recommended. This post hoc analysis evaluates the potential of methylation markers ASCL1 / LHX8 and FAM19A4 / miR124 ‐2 for posttreatment detection of recurrent CIN2 /3. Cervical scrapes taken at 6 and 12 months posttreatment of 364 women treated for CIN2 /3 were tested for methylation of ASCL1 / LHX8 and FAM19A4 / miR124 ‐2 using quantitative multiplex methylation‐specific PCR . Performance of the methylation tests were calculated and compared with the performance of HPV and/or cytology. Methylation levels of recurrent CIN were compared between women with a persistent HPV infection, and women with an incident HPV infection or without HPV infection. Recurrent CIN2 /3 was detected in 42 women (11.5%), including 28 women with CIN2 and 14 with CIN3 . ASCL1 / LHX8 tested positive in 13/14 (92.9%) of recurrent CIN3 and 13/27 (48.1%) of recurrent CIN2 . FAM19A4 / miR124 ‐2 tested positive in 14/14 (100%) of recurrent CIN3 and 10/27 (37.0%) of recurrent CIN2 . Combined HPV and/or methylation testing showed similar positivity rates as HPV and/or cytology. The CIN2 /3 risk at 12 months posttreatment was 30.8% after a positive ASCL1 / LHX8 result at 6 months posttreatment. Methylation levels of CIN2 /3 in women with a persistent HPV infection were significantly higher compared with women with an incident or no HPV infection. In conclusion, posttreatment monitoring by methylation analysis of ASCL1 / LHX8 and FAM19A4 / miR124 ‐2 showed a good performance for the detection of recurrent CIN . DNA methylation testing can help to identify women with recurrent CIN that require re‐treatment.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
